<img height="1" width="1" src="https://www.facebook.com/tr?id=841180246705289&amp;ev=PageView &amp;noscript=1">

We measure our impact by patient outcomes and the success of our partners. Learn More 

Dascena and Beckman Coulter receive BARDA funding for algorithm development

October 29, 2019

Beckman Coulter, Inc., a Danaher company, today announced that it has initially been awarded a contract of $1.25 million, with potential to be awarded an additional $6.5 million if all contract options are exercised, from the DRIVe (Division of Research, Innovation, and Ventures) established by the Biomedical Advanced Research and Development Authority (BARDA).

The contract will enable Beckman Coulter, in collaboration with Dascena, Inc, to develop and commercialize a novel machine-learning-based sepsis detection algorithm. By combining novel laboratory test parameter values with electronic health record information, the objective for this next-generation analytic algorithm will be to accurately predict and detect sepsis earlier, with the goals of reducing sepsis mortality through earlier intervention and reducing the total cost of care.

Learn more here


Interested in learning more?

Proud sponsor of Sepsis Alliance